Printer Friendly

AMERICAN BIOGENETIC SCIENCES APPOINTS THREE VICE PRESIDENTS

      AMERICAN BIOGENETIC SCIENCES APPOINTS THREE VICE PRESIDENTS
    NOTRE DAME, Ind., Nov. 15 /PRNewswire/ -- American Biogenetic Sciences, Inc. (ABS) (NASDAQ: MABXA) today announced the appointment of three vice presidents.
    Dr. Paul Gargan was promoted to vice president-cardiovascular products development.  Gargan has a Ph.D. from Queens University of Belfast, North Ireland, and since 1984 has directed the development of the in vitro fibrinogen diagnostic test known as Cadkit.  Cadkit, ABS' first commercial product, assesses the risk of heart attack or stroke. The market for such a test is estimated to be $400 million.
    Dr. James McLinden was promoted to vice president-molecular biology. McLinden has a Ph.D. from the University of Kansas.  Since 1987, he has directed the company's vaccine research projects and has demonstrated the ability to produce a non-infectious recombinant Hepatitis A vaccine.
    Frances Giambanco was promoted to vice president-administration. Giambanco has a B.S. in business administration from Long Island University and is completing her master's degree.  She is also a management instructor at Dale Carnegie Institute and prior to joining ABS was vice president-administration for TII Industries, Inc. Giambanco's administrative and marketing skills have succeeded in achieving significant public awareness of ABS since the company's initial public offering in May 1990.
    Alfred J. Roach, chairman of ABS, commented, "The company is on the threshold of dynamic growth ad these outstanding appointments will help further our corporate objectives."
    ABS is a biopharmaceutical company which conducts research at the University of Notre Dame, and Trinity College, Dublin, Ireland, to develop and commercialize monoclonal antibody-based products for diagnosing, preventing and treating cardiovascular disease and for diagnosing Alzheimer's disease.  These antibodies are produced from the company's proprietary antigen-minimized mouse colony.  The company is also developing a recombinant vaccine for Hepatitis A.
    -0-        11/15/91
    /CONTACT:  Maureen Murray of American Biogenetic Sciences, 516-789-2600, or Bonnie Sterling of Noonan/Russo Communications, 212-979-9180, for American Biogenetic Sciences/
    (MABXA) CO:  American Biogenetic Sciences, Inc. ST:  Indiana IN:  MTC SU:  PER CK-SM -- NY068 -- 1615 11/15/91 14:26 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 15, 1991
Words:335
Previous Article:U.S. EPA SUPERFUND COMPLETES CLEANUP ON NAVAJO LANDS
Next Article:CYPRUS MINERALS ANNOUNCES PLANS FOR MIAMI SMELTER
Topics:


Related Articles
AMERICAN BIOGENETIC SCIENCES, INC. ANNOUNCES NEW PRESIDENT KENNETH H. BURK, PH.D.
AMERICAN BIOGENETIC SCIENCES APPOINTS NATHAN B. DINCES, Ph.D EXECUTIVE VICE PRESIDENT - CORPORATE DEVELOPMENT
American Biogenetic Sciences Inc. Appoints Stephen H. Ip, Ph.D, Executive Vice President and Chief Operating Officer

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters